<DOC>
	<DOC>NCT00171938</DOC>
	<brief_summary>This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months</brief_summary>
	<brief_title>Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1. Histologically documented diagnosis of GBM. 2. Immunohistochemical documentation of expression of PDGFR. 3. Unresectable, recurrent disease by MRI and spectroscopy 1. Treatment with any other investigational agents within 28 days of first day of study drug dosing. 2. Concurrent chemotherapy. 3. Concurrent radiotherapy. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Brain tumors</keyword>
	<keyword>Imatinib</keyword>
	<keyword>PDGFR</keyword>
</DOC>